Identification

Name
Benzthiazide
Accession Number
DB00562  (APRD00728)
Type
Small Molecule
Groups
Approved
Description

Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Structure
Thumb
Synonyms
  • 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide
  • 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
  • 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
  • 6-chloro-1,1-dioxo-3-(Phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide
  • 6-chloro-7-Sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
  • Benzothiazide
  • Benzotiazida
  • Benzthiazid
  • Benzthiazide
  • Benzthiazidum
  • Benztiazide
External IDs
P 1393
International/Other Brands
Aquatag / Dihydrex / Diucen / Edemax / Exna / Foven
Categories
UNII
1TD8J48L61
CAS number
91-33-8
Weight
Average: 431.937
Monoisotopic: 430.983495728
Chemical Formula
C15H14ClN3O4S3
InChI Key
NDTSRXAMMQDVSW-UHFFFAOYSA-N
InChI
InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
IUPAC Name
3-[(benzylsulfanyl)methyl]-6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1

Pharmacology

Indication

For the treatment of high blood pressure and management of edema.

Pharmacodynamics

Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like benzthiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of benzthiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
UCarbonic anhydrase 9
inhibitor
Human
UCarbonic anhydrase 12
inhibitor
Human
Absorption

Absorbed in the digestive tract.

Volume of distribution
Not Available
Protein binding

30%

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include nausea, vomiting, fatigue, urinary problems and drowsiness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Benzthiazide.Experimental
(4R)-limoneneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Benzthiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Benzthiazide.Experimental, Illicit
1alpha-Hydroxyvitamin D5The risk or severity of hyperkalemia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Benzthiazide.Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Benzthiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Benzthiazide.Experimental, Illicit
AbediterolAbediterol may increase the hypokalemic activities of Benzthiazide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Benzthiazide.Approved, Investigational
AceclofenacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Benzthiazide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Benzthiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Benzthiazide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Benzthiazide.Experimental
AlclofenacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Benzthiazide.Approved
AlcuroniumThe serum concentration of Benzthiazide can be increased when it is combined with Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Benzthiazide.Experimental, Investigational
AlfacalcidolThe risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Benzthiazide.Approved, Nutraceutical
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Benzthiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Benzthiazide.Approved
AlminoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Benzthiazide.Approved
AmcinonideAmcinonide may increase the hypokalemic activities of Benzthiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Illicit
AndrographolideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Benzthiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Benzthiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Benzthiazide.Investigational
AnisodamineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Benzthiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Benzthiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Benzthiazide.Investigational
AtracuriumThe serum concentration of Benzthiazide can be increased when it is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe serum concentration of Benzthiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Benzthiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Benzthiazide.Investigational
BalsalazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Benzthiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Benzthiazide.Illicit
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
BecocalcidiolThe risk or severity of hyperkalemia can be increased when Becocalcidiol is combined with Benzthiazide.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Benzthiazide.Investigational
BenactyzineThe serum concentration of Benzthiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Benzthiazide can be increased when it is combined with Benzatropine.Approved
BenzydamineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Benzydamine.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bevonium.Experimental
BiperidenThe serum concentration of Benzthiazide can be increased when it is combined with Biperiden.Approved, Investigational
BitolterolBitolterol may increase the hypokalemic activities of Benzthiazide.Withdrawn
BornaprineThe serum concentration of Benzthiazide can be increased when it is combined with Bornaprine.Experimental
BromfenacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Benzthiazide.Approved
BufexamacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Benzthiazide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bumadizone.Experimental
ButylscopolamineThe serum concentration of Benzthiazide can be increased when it is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CalcidiolThe risk or severity of hyperkalemia can be increased when Calcidiol is combined with Benzthiazide.Approved, Nutraceutical
CalcipotriolThe risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Benzthiazide.Approved
CalcitriolThe risk or severity of hyperkalemia can be increased when Calcitriol is combined with Benzthiazide.Approved, Nutraceutical
Calcium AcetateBenzthiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Investigational
Calcium CarbonateBenzthiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Investigational
Calcium ChlorideBenzthiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium CitrateBenzthiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateBenzthiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateBenzthiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateBenzthiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateBenzthiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Investigational, Vet Approved
Calcium lactate gluconateBenzthiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium levulinateBenzthiazide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.Approved, Experimental
Calcium pangamateBenzthiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateBenzthiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Benzthiazide.Approved
CandoxatrilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Benzthiazide.Experimental
CarprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CaseinBenzthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenoxamineThe serum concentration of Benzthiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Benzthiazide.Approved, Investigational
CholecalciferolThe risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Benzthiazide.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Benzthiazide.Experimental
CilazaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Cilazapril.Approved
CitalopramCitalopram may increase the hyponatremic activities of Benzthiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Benzthiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Benzthiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Benzthiazide.Approved
ClonixinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Clonixin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Benzthiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Benzthiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
CurcuminThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclopentolateThe serum concentration of Benzthiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of severe leukopenia can be increased when Benzthiazide is combined with Cyclophosphamide.Approved, Investigational
CymarinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Cymarin.Experimental
DapoxetineDapoxetine may increase the hyponatremic activities of Benzthiazide.Investigational
DarifenacinThe serum concentration of Benzthiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
DelaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Benzthiazide.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Benzthiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesonideDesonide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Benzthiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Benzthiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Benzthiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
DexamethasoneDexamethasone may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Benzthiazide.Vet Approved
DexetimideThe serum concentration of Benzthiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Benzthiazide can be increased when it is combined with Dicyclomine.Approved
DifenpiramideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Benzthiazide.Approved
DiflunisalThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Benzthiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Benzthiazide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Benzthiazide.Approved
DiphenhydramineThe serum concentration of Benzthiazide can be increased when it is combined with Diphenhydramine.Approved, Investigational
DipivefrinDipivefrin may increase the hypokalemic activities of Benzthiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Benzthiazide.Approved
DofetilideBenzthiazide may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DoxercalciferolThe risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Benzthiazide.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
DroxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Benzthiazide.Approved, Investigational
DuloxetineDuloxetine may increase the hyponatremic activities of Benzthiazide.Approved
DuvelisibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Benzthiazide can be decreased when used in combination with E-6201.Investigational
EldecalcitolThe risk or severity of hyperkalemia can be increased when Eldecalcitol is combined with Benzthiazide.Investigational
ElocalcitolThe risk or severity of hyperkalemia can be increased when Elocalcitol is combined with Benzthiazide.Investigational
EmeproniumThe serum concentration of Benzthiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Benzthiazide.Approved
EnalaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of hypotension can be increased when Benzthiazide is combined with Enalaprilat.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Benzthiazide.Experimental
EphedraEphedra may increase the hypokalemic activities of Benzthiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Epirizole.Approved
EquileninEquilenin may increase the hypokalemic activities of Benzthiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Benzthiazide.Approved
ErgocalciferolThe risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Benzthiazide.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Benzthiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Benzthiazide.Approved
EtafedrineEtafedrine may increase the hypokalemic activities of Benzthiazide.Approved
EtanautineThe serum concentration of Benzthiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Benzthiazide.Approved
EthenzamideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Benzthiazide can be increased when it is combined with Ethopropazine.Approved
EtodolacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Benzthiazide.Withdrawn
EtoricoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtybenzatropineThe serum concentration of Benzthiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Benzthiazide.Approved, Investigational
ExisulindThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FentiazacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Benzthiazide can be increased when it is combined with Fesoterodine.Approved
FlavoxateThe serum concentration of Benzthiazide can be increased when it is combined with Flavoxate.Approved
FloctafenineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Benzthiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Benzthiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FluoxetineFluoxetine may increase the hyponatremic activities of Benzthiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Benzthiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Benzthiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Benzthiazide.Approved
FlurbiprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Benzthiazide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Benzthiazide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Benzthiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
FosinoprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Fosinopril.Approved
GallamineThe serum concentration of Benzthiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Benzthiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Benzthiazide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Benzthiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Benzthiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Benzthiazide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Benzthiazide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Benzthiazide.Approved
GlycopyrroniumThe serum concentration of Benzthiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Guacetisal.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Benzthiazide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Benzthiazide.Investigational
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved
HexoprenalineHexoprenaline may increase the hypokalemic activities of Benzthiazide.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Benzthiazide can be increased when it is combined with Homatropine.Approved
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
HyoscyamineThe serum concentration of Benzthiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Icatibant.Approved, Investigational
ImidaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Benzthiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Benzthiazide.Investigational, Withdrawn
IndobufenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Indoprofen.Withdrawn
InecalcitolThe risk or severity of hyperkalemia can be increased when Inecalcitol is combined with Benzthiazide.Experimental, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Benzthiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Benzthiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Benzthiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Benzthiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Benzthiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Benzthiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Benzthiazide.Approved
IpratropiumThe serum concentration of Benzthiazide can be increased when it is combined with Ipratropium bromide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Benzthiazide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
IsoxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Isoxicam.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Benzthiazide.Investigational
IvabradineBenzthiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Kebuzone.Experimental
KetoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ketorolac.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Benzthiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Benzthiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Benzthiazide.Approved
LisinoprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumBenzthiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LonazolacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Benzthiazide.Approved
LoxoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Masoprocol.Approved, Investigational
MaxacalcitolThe risk or severity of hyperkalemia can be increased when Maxacalcitol is combined with Benzthiazide.Approved, Investigational
MazaticolThe serum concentration of Benzthiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Benzthiazide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Benzthiazide.Approved
Mefenamic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Benzthiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Benzthiazide.Approved
MethanthelineThe serum concentration of Benzthiazide can be increased when it is combined with Methantheline.Approved, Investigational
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Benzthiazide.Approved
MethscopolamineThe serum concentration of Benzthiazide can be increased when it is combined with Methscopolamine.Approved
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
Methylscopolamine bromideThe serum concentration of Benzthiazide can be increased when it is combined with Methylscopolamine bromide.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Metildigoxin.Experimental
MetixeneThe serum concentration of Benzthiazide can be increased when it is combined with Metixene.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Benzthiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Benzthiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Benzthiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
Mycophenolate mofetilThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Naftifine.Approved
NaproxenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Benzthiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Benzthiazide.Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Benzthiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nepafenac.Approved, Investigational
NifenazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nitroaspirin.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Benzthiazide.Approved
OleandrinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Benzthiazide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Benzthiazide.Approved
OlopatadineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatThe risk or severity of hypotension can be increased when Benzthiazide is combined with Omapatrilat.Investigational
OrciprenalineOrciprenaline may increase the hypokalemic activities of Benzthiazide.Approved
OrgoteinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Benzthiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Benzthiazide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of hyponatremia can be increased when Benzthiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Benzthiazide can be increased when it is combined with Oxitropium.Investigational
OxybutyninThe serum concentration of Benzthiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxyphenbutazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Benzthiazide can be increased when it is combined with Oxyphenonium.Approved
PalmidrolThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumThe serum concentration of Benzthiazide can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Benzthiazide.Approved
ParecoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Parecoxib.Approved
ParicalcitolThe risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Benzthiazide.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Benzthiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Parthenolide.Approved, Investigational
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Investigational, Vet Approved
PentoliniumThe serum concentration of Benzthiazide can be increased when it is combined with Pentolinium.Approved
PerindoprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Peruvoside.Experimental
PF-00610355PF-00610355 may increase the hypokalemic activities of Benzthiazide.Investigational
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Benzthiazide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Benzthiazide can be increased when it is combined with Phenglutarimide.Experimental
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Investigational
PhenylbutazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Benzthiazide.Approved, Investigational
PipecuroniumThe serum concentration of Benzthiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Benzthiazide.Approved
PirenzepineThe serum concentration of Benzthiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiroxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Pirprofen.Experimental
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Benzthiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Benzthiazide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Benzthiazide.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Benzthiazide.Approved, Experimental, Investigational
PrimidonePrimidone may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
ProcyclidineThe serum concentration of Benzthiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropanthelineThe serum concentration of Benzthiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Benzthiazide can be increased when it is combined with Propiverine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
PTC299The therapeutic efficacy of Benzthiazide can be decreased when used in combination with PTC299.Investigational
QuinaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Benzthiazide can be increased when it is combined with Quinidine.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Benzthiazide.Approved
RamiprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Ramipril.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Benzthiazide.Approved, Investigational
RescinnamineThe risk or severity of hypotension can be increased when Benzthiazide is combined with Rescinnamine.Approved
ResveratrolThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Benzthiazide.Approved
RitodrineRitodrine may increase the hypokalemic activities of Benzthiazide.Approved, Investigational
RofecoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Benzthiazide.Approved, Investigational
SalbutamolSalbutamol may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Benzthiazide.Approved
SalsalateThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Benzthiazide.Approved
ScopolamineThe serum concentration of Benzthiazide can be increased when it is combined with Scopolamine.Approved, Investigational
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Vet Approved
SemapimodThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Benzthiazide.Experimental, Investigational
SeratrodastThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Benzthiazide.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Benzthiazide.Approved, Investigational
SolifenacinThe serum concentration of Benzthiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Benzthiazide.Investigational
SpiraprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Spirapril.Approved
SRT501The therapeutic efficacy of Benzthiazide can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Sulfasalazine.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Benzthiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Suxibuzone.Experimental
TacalcitolThe risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Benzthiazide.Experimental, Investigational
TarenflurbilThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tarenflurbil.Investigational
TemocaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Benzthiazide.Approved
TeriflunomideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Teriflunomide.Approved
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Benzthiazide.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TinoridineThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Benzthiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Benzthiazide.Approved, Withdrawn
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Benzthiazide.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Benzthiazide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tolmetin.Approved
TolterodineThe serum concentration of Benzthiazide can be increased when it is combined with Tolterodine.Approved, Investigational
ToremifeneBenzthiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tranilast.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Benzthiazide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tribenoside.Experimental
TrihexyphenidylThe serum concentration of Benzthiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimethaphanThe serum concentration of Benzthiazide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Benzthiazide.Investigational, Withdrawn
TropatepineThe serum concentration of Benzthiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Benzthiazide can be increased when it is combined with Tropicamide.Approved, Investigational
TrospiumThe serum concentration of Benzthiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Benzthiazide can be increased when it is combined with Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Benzthiazide.Approved
UmeclidiniumThe serum concentration of Benzthiazide can be increased when it is combined with Umeclidinium.Approved
ValdecoxibThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
VecuroniumThe serum concentration of Benzthiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Benzthiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Benzthiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Benzthiazide.Approved, Investigational
Vitamin DThe risk or severity of hyperkalemia can be increased when Vitamin D is combined with Benzthiazide.Approved, Nutraceutical, Vet Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Benzthiazide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Benzthiazide.Withdrawn
ZofenoprilThe risk or severity of hypotension can be increased when Benzthiazide is combined with Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Samuel M. Fainberg, Porfirio F. Perez, "Stable solution of benzthiazide (3-[benzythiol methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide) suitable for parenteral administration and process of preparation." U.S. Patent US4022894, issued May 10, 1977.

US4022894
General References
Not Available
External Links
Human Metabolome Database
HMDB0014702
KEGG Drug
D00651
KEGG Compound
C07759
PubChem Compound
2343
PubChem Substance
46506752
ChemSpider
2253
ChEBI
3047
ChEMBL
CHEMBL1201039
Therapeutic Targets Database
DAP000603
PharmGKB
PA164776841
Wikipedia
Benzthiazide
ATC Codes
G01AE10 — Combinations of sulfonamides

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Solvay pharmaceuticals
  • Private formulations inc
  • Ah robins inc
  • Pfizer laboratories div pfizer inc
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)210-211McLamore, W.M. and Laubach, G.D.; U.S. Patent 3,111,517; November 19, 1963; assigned to Chas. Pfizer & Co., Inc.
water solubility8.91 mg/LNot Available
logP1.73BERTHOD,A ET AL. (1999)
pKa6BERTHOD,A ET AL. (1999)
Predicted Properties
PropertyValueSource
Water Solubility0.0129 mg/mLALOGPS
logP2.26ALOGPS
logP1.84ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)8.77ChemAxon
pKa (Strongest Basic)1.25ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.69 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.14 m3·mol-1ChemAxon
Polarizability41.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9593
Blood Brain Barrier-0.8349
Caco-2 permeable-0.705
P-glycoprotein substrateSubstrate0.5849
P-glycoprotein inhibitor INon-inhibitor0.7928
P-glycoprotein inhibitor IINon-inhibitor0.5851
Renal organic cation transporterNon-inhibitor0.6761
CYP450 2C9 substrateNon-substrate0.7261
CYP450 2D6 substrateNon-substrate0.8285
CYP450 3A4 substrateNon-substrate0.557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.7652
CYP450 2D6 inhibitorNon-inhibitor0.8733
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.681
Ames testNon AMES toxic0.8436
CarcinogenicityNon-carcinogens0.7729
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.6663 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9085
hERG inhibition (predictor II)Non-inhibitor0.879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-06r6-9624000000-532194fb14045a87f8de
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Organosulfonamides / Imidolactams / Benzene and substituted derivatives / Aryl chlorides / Aminosulfonyl compounds / Sulfenyl compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds
show 3 more
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Organosulfonic acid amide / Imidolactam / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, benzothiadiazine (CHEBI:3047)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA12
Uniprot ID
O43570
Uniprot Name
Carbonic anhydrase 12
Molecular Weight
39450.615 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 06:37